TY - JOUR
T1 - Chronopharmacological Study of a Nonsedative H1-blocking Agent (WAL 801 CL, Epinastine)
AU - Nakano, Shigeyuki
AU - Naruo, Tetsuro
AU - Watanabe, Kouki
AU - Takaoka, Nobuyuki
AU - Ohdo, Shigehiro
AU - Ogawa, Nobuya
AU - Miyauchi, Shunji
AU - Miki, Yoshiharu
PY - 1991
Y1 - 1991
N2 - The dose-response relation (study I) and the effect of the timing of administration (study II) with respect to the antihistaminic activity of a Hi-blocking agent, WAL 801 CL (Epinastine), were investigated. In study I, a 10, 20, and 40 mg dose of WAL 801 CL or a placebo was administered to 11 healthy male volunteer students (X±SD = 23. 3 ±1.3 yrs) after breakfast (8: 30) by a double-blind fashion using the Latin square design, and the histamine intradermal reaction and psychomotor functions were subsequently examined. In study II, either 20 mg of WAL 801 CL or a placebo were administeredto 8 healthy male volunteer students (23.8±1.4 yrs) after breakfast (8:00) or after dinner (20:30) in the same way as in Study I, and the histamine intradermal reaction was subsequently examined. WAL 801 CL inhibited the histamine intradermal reaction dose-dependently, and no findings suggesting any effects on the CNS were observed. The inhibitory effect of WAL 801 CL on the histamine intradermal reaction tended to last longer when it was administered in the morning, while the effect tended to be stronger when it was administered in the evening, but the differences were not significant. Thus the results show that WAL 801 CL is a nonsedative Hi-blocking agent and that the timing of administration does not critically influence the antihistaminic activity of the drug.
AB - The dose-response relation (study I) and the effect of the timing of administration (study II) with respect to the antihistaminic activity of a Hi-blocking agent, WAL 801 CL (Epinastine), were investigated. In study I, a 10, 20, and 40 mg dose of WAL 801 CL or a placebo was administered to 11 healthy male volunteer students (X±SD = 23. 3 ±1.3 yrs) after breakfast (8: 30) by a double-blind fashion using the Latin square design, and the histamine intradermal reaction and psychomotor functions were subsequently examined. In study II, either 20 mg of WAL 801 CL or a placebo were administeredto 8 healthy male volunteer students (23.8±1.4 yrs) after breakfast (8:00) or after dinner (20:30) in the same way as in Study I, and the histamine intradermal reaction was subsequently examined. WAL 801 CL inhibited the histamine intradermal reaction dose-dependently, and no findings suggesting any effects on the CNS were observed. The inhibitory effect of WAL 801 CL on the histamine intradermal reaction tended to last longer when it was administered in the morning, while the effect tended to be stronger when it was administered in the evening, but the differences were not significant. Thus the results show that WAL 801 CL is a nonsedative Hi-blocking agent and that the timing of administration does not critically influence the antihistaminic activity of the drug.
UR - http://www.scopus.com/inward/record.url?scp=0025939206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025939206&partnerID=8YFLogxK
U2 - 10.3999/jscpt.22.617
DO - 10.3999/jscpt.22.617
M3 - Article
AN - SCOPUS:0025939206
VL - 22
SP - 617
EP - 626
JO - Japanese Journal of Clinical Pharmacology and Therapeutics
JF - Japanese Journal of Clinical Pharmacology and Therapeutics
SN - 0388-1601
IS - 3
ER -